Ignite Creation Date:
2024-05-06 @ 7:12 PM
Last Modification Date:
2024-10-26 @ 3:02 PM
Study NCT ID:
NCT05924256
Status:
RECRUITING
Last Update Posted:
2024-03-15
First Post:
2023-06-21
Brief Title:
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single-center open-label phase 2 study to evaluate the efficacy and safety of target therapy for patients with relapsedmetastastic salivary gland carcinoma based on molecular typing
Detailed Description:
Patients with IHC HER2 IHC 3 or IHC 2ISH will be located into arm 1 to receive anti-her2 ADCSHR- A1811 Patients with IHC AR positive will be located into arm 2 to receive anti-androgen therapy SHR-3680leuprolide Patients with HER2 negative and AR negative will be located into arm 3 to receive anti-TROP2 ADC SHR-A1921 Patients with IHC HER2 IHC 1 or IHC 2ISH- will be located into arm 4 to receive anti-her2 ADCSHR- A1811
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None